Shares of Zentalis Pharmaceuticals, Inc. (ZNTL) gained nearly 14% on Wednesday morning after the clinical-stage biopharmaceutical company announced a $25 million equity investment from Pfizer Inc. (PFE). Both the companies also plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells.
ZNTL is currently trading at $24.87, up $3.03 or 13.87%, on the Nasdaq, on a volume of 1.1 million shares, above average volume of 0.5 million. The stock had opened its trading at $24.31 after closing Tuesday's trading at $21.84. The stock has traded between $21.18 and $87.19 in the past 52-week period.
Zentalis agreed to sell 953,834 of its common shares at a price of $26.21 per share to Pfizer for proceeds of $25.0 million.
The proceeds will help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes.
With prioritization of the clinical development of ZN-c3 and ZN-d5, budget reallocation and Pfizer's investment.
Both the company have entered into an agreement to collaborate to advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells.
Adam Schayowitz, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis' Scientific Advisory Board.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.